UNSPSC 51172712: Hyoscyamus/phenazopyridine/sulfamethizole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.

UNSPSC 51172712 Hyoscyamus/phenazopyridine/sulfamethizole is a Commodity code that appears in state and local procurement tied to drug testing and pharmaceutical supply, though the recent opportunities show minimal direct sourcing of this specific formulation. Collin County Community Supervision and Corrections Department posted an RFP in July 2026 for offender specimen collection and drug testing services, which includes immunoassay screening, LC/MS/MS or GC/MS confirmation, and alternative testing methodologies—work that may involve this drug class in confirmatory or reference testing, though the RFP does not name it explicitly. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription fulfillment models, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon. The mix of issuing bodies—county criminal justice departments, state health authorities, and cooperative purchasing alliances—indicates that this code, when active, spans corrections, healthcare, and multi-jurisdictional procurement.

Activity under this code concentrates in Texas and the Upper Midwest. The Collin County RFP represents the most concrete recent opportunity, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years plus three optional one-year renewals, structured around 25,031 annual tests priced on a per-test basis. The MMCAP cooperative procurement, which extends to Oregon as well as Minnesota, offers broader geographic reach but does not isolate this specific drug in its documented scope. The Texas HHS RFI remains exploratory and does not commit to contract value or timeline. Recent activity suggests this code sees intermittent rather than continuous procurement activity at the state and local level, with opportunities emerging primarily through specialized purchasing vehicles—cooperative alliances and department-specific clinical or correctional programs—rather than routine open-market solicitations.